Aphria Releases Q4 Earnings

After the bell Aphria released earnings for Q4 and FY2019. The highlights include:

  • Net revenue of $128.6 million in the fourth quarter, an increase of 75% from prior quarter and 969% from prior year.
  • $99.2 million worth of distribution sales from CC Pharma, a German medical marijuana distributor, and other distribution outfits.
  • Revenue for adult-use cannabis of $18.5 million in the fourth quarter, up 158% from prior quarter.
  • Settlement of Green Growth Brands takeover bid resulting in $50 million cash received and an additional $39 million to be received in November.
  • The company recorded an operating loss for the year of approximately $145M.
  • The company had a $50M impairment in Goodwill on their LATAM acquisitions on the year.

From the MDAs:

Irwin Simon, CEO, Aphria

Over the last six months, our organization identified immediate priorities to help generate substantial progress near-term and long-term. We built upon existing business fundamentals and capabilities, streamlined processes, strengthened governance, and focused on building brand awareness. Together, we have nurtured an entrepreneurial culture of accountability through data-driven decision-making for value creation in the global medical and adult-use cannabis industry.  Today’s Aphria has a stronger foundation for long-term growth and success.

Irwin Simon, CEO Aphria

The early reactions from Twitter:

And of course, not all positive with long time FinTwit’s
Jonathan Goldsmith fanboy stating:

More to come later.


Information for this briefing was found via Sedar and Twitter. The author is short Aprhia via Puts and has no affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Small Cap Steve

SmallCapSteve started blogging in the Winter of 2009. During that time, he was able to spot many take over candidates and pick a variety of stocks that generated returns in excess of 200%. Today he consults with microcap companies helping them with capital markets strategy and focuses on industries including cannabis, tech, and junior mining.

Share
Tweet
WhatsApp
Share
Reddit